ATTR treatment landscape heats up as clinical progress gathers pace

It has been a busy period for the amyloidosis treatment field. In April, Danish drugmaker Novo Nordisk (NOV: N) received US Food and Drug Administration (FDA) Fast Track designation for coramitug, its investigational treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). In March, UK biotech company Immutrin raised £65 million ($87 million) in a Series A round to advance its amyloidosis antibody program.

Both developments point to rising biopharma interest in a small but growing disease area. Much of that attention has been driven by better diagnosis, greater disease awareness, new treatment options and the increasing prevalence of transthyretin amyloidosis (ATTR) as populations age.